So I look at the Basel, I look at the pump as probably good drivers for us in ’24, ’25, but we’ve got multiple growth verticals here on this platform, like I’ve said. To your question on IQVIA, I think anybody who kind of follows pharma and is more attuned to pharma knows that IQVIA doesn’t pick up the entire market. So the pharmacy channel in the U.S. gets picked up by IQVIA, but there are other segments in the market that drive adoption that don’t get picked up by IQVIA. So maybe that’s what you’re seeing.
Operator: Thank you. Our next question will come from Danielle Antalffy from UBS. Your line is open.
Danielle Antalffy: Hey, good morning, guys. Thanks so much for taking the question. Congrats on a strong end of the year and strong guidance. Just, Robert, since this story seems to be very much about supply and growth, I haven’t heard you reference the Fab 5, one of my favorite analogies in a long time. So just wanted to, and maybe I just missed it, but just wanted to get an update on those five products or where you think you guys are in launch trajectories, revenue contribution for each of those products. Do you still think they’re the Fab 5 and where, how they sort of factor into the growth, the 8 to 10% organic growth for 2024? Thanks so much.
Robert Ford: Yes, thanks. I don’t know if I regret using that terminology or not now, Danielle, but I guess I would say yes, they are great products. And we didn’t think about calling them that because there were going to be a flash in the pan for, one or two years. We look at these as really long-term great growth opportunities that we have that will significantly add to the Company, over the next few years. And, quite frankly, they have added a good amount of growth for us this year and they’ll accelerate. So I think this year, sorry, in 2023, those five products that represented about half a point of growth, I expect that to increase in 2024 to about, about a point of growth, total Abbott, contribution. So they’re definitely stepping up.
And I’d say some of them I would call market creating opportunities, Tricuspid, I would put over there, CardioMEMS over there, generating the clinical data, generating the data for reimbursement, generating referral pathways. We know how to do this and we all want things to go pretty fast, especially with MedTech products, right? But with products like this that have such significant growth opportunities, there’s a certain amount of work that you need to do regarding clinical work as it relates to, market expansion, development and market development. I’d say some of the other products on that list, I’d say are probably more market conversion. And, these are already attractive, large, attractive growth segments that, that we’re targeting with our technologies, Navitor in the Tavr space, Aveir in the CRM side.
These are large segments that, we’re coming in and we’ll have different value propositions. I think Aveir has got a tremendous opportunity. It’s a $3 billion global pacing market and the value proposition for Aveir, I think, is second to none in terms of its proposition to the implanter, to the patient. So, I expect a lot from Aveir in terms of growth. I expect a lot from, Navitor. And, we’re going to be expanding, so we’ll have two new line extensions to Navitor this year, Navitor Vision and Navitor Titan. And so, we’re investing in those areas and, yes, they’re still great products. They’ll still have the Fab 5 on it and they continue to increase. They’ll grow 50%, at least we’re forecasting a 50% growth next year and they’ll contribute about a point of growth to the overall Company.
So, that being said, I will say, those are great products and they take a lot of focus, but we still have, we still have a lot in the chamber here, too, whether it’s Lingo, whether it’s our TBI test, we’re going to be launching a nutritional drink for GLP-1 users this year. Also, we’re doing a lot of work on Volt, which is our PFA solution. We put out some announcements already at the beginning of the year regarding our clinical trials. I talked about biosimilars in EPD, our dual analyte sensor for Libre. We’re developing a new Alinity system to target a segment of the diagnostic market that we’re currently not competing. So, yes, Fab 5, a lot of great contributions, but there’s a lot in the chamber here and I think that’s really what’s going to sustain our growth beyond 2024 and 2025 is just having a robust pipeline.
